Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Walter J. Curran"'
Autor:
Xingming Deng, Fadlo R. Khuri, Walter J. Curran, Suresh S. Ramalingam, Gabriel L. Sica, Taofeek K. Owonikoko, Zhuo G. Chen, Shi-Yong Sun, Zhongliang Hu, Rui Li
The emergence of resistance to EGF receptor (EGFR) inhibitor therapy is a major clinical problem for patients with non–small cell lung cancer (NSCLC). The mechanisms underlying tumor resistance to inhibitors of the kinase activity of EGFR are not f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a7038fca0d55be0680a0cf5f30dbfa7
https://doi.org/10.1158/1535-7163.c.6535810
https://doi.org/10.1158/1535-7163.c.6535810
Autor:
Xingming Deng, Fadlo R. Khuri, Walter J. Curran, Suresh S. Ramalingam, Gabriel L. Sica, Taofeek K. Owonikoko, Zhuo G. Chen, Shi-Yong Sun, Zhongliang Hu, Rui Li
PDF file, 171K, Inhibition of EGFR by erlotinib (Erlo) results in STAT3 phosphorylation at Tyr 705 and increased Bcl2/Bcl-XL in human lung cancer H1650 and H1975 cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::837e93a1594b063d59527bed9e65eb20
https://doi.org/10.1158/1535-7163.22498159
https://doi.org/10.1158/1535-7163.22498159
Autor:
Xingming Deng, Fadlo R. Khuri, Walter J. Curran, Suresh S. Ramalingam, Gabriel L. Sica, Taofeek K. Owonikoko, Zhuo G. Chen, Shi-Yong Sun, Zhongliang Hu, Rui Li
PDF file, 46K, Structures of erlotinib and niclosamide.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b7709e1c4703469d6da0d3bc56b547f
https://doi.org/10.1158/1535-7163.22498156.v1
https://doi.org/10.1158/1535-7163.22498156.v1
Autor:
Xingming Deng, Fadlo R. Khuri, Walter J. Curran, Suresh S. Ramalingam, Gabriel L. Sica, Taofeek K. Owonikoko, Zhuo G. Chen, Shi-Yong Sun, Zhongliang Hu, Rui Li
PDF file, 78K, Treatment of mice with human lung cancer HCC827/ER xenografts using a combination of erlotinib and niclosamide results in a long term tumor-free survival.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1edf04b65457e9318692a21d1116d6c5
https://doi.org/10.1158/1535-7163.22498153
https://doi.org/10.1158/1535-7163.22498153
Autor:
Xingming Deng, Fadlo R. Khuri, Walter J. Curran, Suresh S. Ramalingam, Gabriel L. Sica, Taofeek K. Owonikoko, Zhuo G. Chen, Shi-Yong Sun, Zhongliang Hu, Rui Li
PDF file, 152K, Toxicity analysis for treatments with erlotinib and niclosamide in mice bearing HCC827/ER xenografts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::845bf9f2ea76656ef1661a49a22b7a00
https://doi.org/10.1158/1535-7163.22498147.v1
https://doi.org/10.1158/1535-7163.22498147.v1
Autor:
Xingming Deng, Fadlo R. Khuri, Walter J. Curran, Suresh S. Ramalingam, Gabriel L. Sica, Taofeek K. Owonikoko, Zhuo G. Chen, Shi-Yong Sun, Zhongliang Hu, Rui Li
PDF file, 161K, Toxicity analysis for treatments with erlotinib and niclosamide in mice bearing HCC827 xenografts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0229b6ccefd910e5c08398b19f0018f3
https://doi.org/10.1158/1535-7163.22498150.v1
https://doi.org/10.1158/1535-7163.22498150.v1
Autor:
Xingming Deng, Jia Zhou, Dong M. Shin, Taofeek K. Owonikoko, Walter J. Curran, Fadlo R. Khuri, Haian Fu, Andrew T. Magis, Suresh S. Ramalingam, Gabriel L. Sica, Zhuo G. Chen, Shi-Yong Sun, Adam I. Marcus, Wei Zhou, Melissa Gilbert-Ross, Guojing Zhang, Guo Chen, Ye Ding, Dongkyoo Park, Maohua Xie, Jun Zhang, Chunyong Ding, Rui Li
A rationale exists for pharmacologic manipulation of the serine (S)184 phosphorylation site of the proapoptotic Bcl2 family member Bax as an anticancer strategy. Here, we report the refinement of the Bax agonist SMBA1 to generate CYD-2-11, which has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d09e6f8b4e77f32ca61f6be4c27d83d
https://doi.org/10.1158/0008-5472.c.6509121.v1
https://doi.org/10.1158/0008-5472.c.6509121.v1
Autor:
Xingming Deng, Walter J. Curran, Zhengjia Chen, Chao Zhang, Keqiang Ye, Gabriel L. Sica, Taofeek K. Owonikoko, Suresh S. Ramalingam, Madhusmita Behera, Andrew T. Magis, Dongkyoo Park, Guo Chen
Mcl-1 is a unique antiapoptotic Bcl2 family protein that functions as a gatekeeper in manipulating apoptosis and survival in cancer cells. Akt is an oncogenic kinase that regulates multiple cellular functions and its activity is significantly elevate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c52fb4f8f47903bc495a90b19ba67a6b
https://doi.org/10.1158/0008-5472.c.6511107.v1
https://doi.org/10.1158/0008-5472.c.6511107.v1
Autor:
Xingming Deng, Walter J. Curran, Zhengjia Chen, Chao Zhang, Keqiang Ye, Gabriel L. Sica, Taofeek K. Owonikoko, Suresh S. Ramalingam, Madhusmita Behera, Andrew T. Magis, Dongkyoo Park, Guo Chen
Supplementary Figure 1. Knockout of Mcl-1 from H1299 by CRISPR/Cas9 system results in decreased cell proliferation and increased caspase 3/7 activity. Supplementary Figure 2. Expression of constitutive active form of Akt in H1299 Mcl-1 knockout cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94706763e986d80290c0f157a9e89048
https://doi.org/10.1158/0008-5472.22422006.v1
https://doi.org/10.1158/0008-5472.22422006.v1